XML 47 R21.htm IDEA: XBRL DOCUMENT v3.20.1

Revenues (Tables)

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three months ended March 31, 2020 and 2019:

															Three months ended March 31,
															2020						2019
Products:
Acetadote															$	713,899					$	849,502
Omeclamox-Pak															114,770						199,537
Kristalose															3,311,696						3,307,658
Vaprisol															208,763						286,676
Caldolor															1,096,291						1,317,074
Vibativ															2,425,755						2,060,195
Other revenue															459,560						709,218
Total net revenues															$	8,330,734					$	8,729,860

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration